2-(4-羟基苯基)苯并[B]噻吩-6-醇

中文名称:

2-(4-羟基苯基)苯并[B]噻吩-6-醇

中文同义词:

2-(4-羟苯基)-苯并[B]噻吩-6-醇;2-(4-羟基苯基)苯并[B]噻吩-6-醇;雷洛昔芬杂质4;雷洛昔芬杂质8;2-(4-羟苯基)苯并[B]噻吩-6-醇

英文名称:

2-(4-Hydroxyphenyl)benzo[b]thiophene-6-ol

英文同义词:

2-(4-Hydroxyphenyl)benzo[b]thiophene-6-ol;2-(4-hydroxyphenyl)-1-benzothiophene-6-ol;Raloxifene InterMediate;2-(4-Hydroxyphenyl)benzo[b]thiophen-6-ol;6-Hydroxy-2-(4-Hydroxyphenyl)Benzo[B]Thiophene;2-(4-hydroxyphenyl)-1-benzothiophen-6-ol;Raloxifene Impurity 4;2-(4-Hydroxyphenyl)benzothiophene-6-ol

CAS号:

63676-22-2

分子式:

C14H10O2S

分子量:

242.29

EINECS号:

相关类别:

医药中间体

Mol文件:

63676-22-2.mol

熔点 

295 °C(dec.)

沸点 

477.0±30.0 °C(Predicted)

密度 

1.383

储存条件 

Keep in dark place,Inert atmosphere,Store in freezer, under -20°C

酸度系数(pKa)

9.32±0.15(Predicted)

生物活性

Estrogen receptor modulator 1 (compound 18) 是一种口服活性的选择性 estrogen receptor 调节剂(SERM)，pIC50值为0.46。Estrogen receptor modulator 1具有潜在的抗肿瘤活性。

靶点

Target Value ER (Cell-free assay) 0.46(pIC50)

Target

Value

ER (Cell-free assay)

0.46(pIC50)

体外研究

Estrogen receptor modulator 1 (compound 18) (100 nM; 10 days) inhibits T47D:A18/PKCα and T47D:A18-TAM1 colony formation. Estrogen receptor modulator 1 (100 nM; 9 days) significantly inhibits the growth of MCF-7:5C cell, and induces apoptosis in these cells 6 days. Cell Proliferation Assay Cell Line: T47D:A18/PKCα and T47D:A18-TAM1 cells Concentration: 100 nM Incubation Time: 10 days Result: Inhibit T47D:A18/PKCα and T47D:A18-TAM1 colony formation. Cell Viability Assay Cell Line: MCF-7:5C cells Concentration: 100 nM Incubation Time: 9 days Result: Significantly inhibited the growth of MCF-7:5C cells.

Cell Line:

T47D:A18/PKCα and T47D:A18-TAM1 cells

Concentration:

100 nM

Incubation Time:

10 days

Result:

Inhibit T47D:A18/PKCα and T47D:A18-TAM1 colony formation.

Cell Line:

MCF-7:5C cells

Concentration:

100 nM

Incubation Time:

9 days

Result:

Significantly inhibited the growth of MCF-7:5C cells.

体内研究

Estrogen receptor modulator 1 (1.5 mg/animal; p.o. ; daily for 2 weeks) results in regression of T47D:A18/PKCα tumors. Animal Model: 4-6 week old athymic mice (Harlan-Sprague-Dawley) Dosage: 1.5 mg/animal Administration: p.o. ; daily for 2 weeks Result: Significantly reduced tumor volume.

Animal Model:

4-6 week old athymic mice (Harlan-Sprague-Dawley)

Dosage:

1.5 mg/animal

Administration:

p.o. ; daily for 2 weeks

Result:

Significantly reduced tumor volume.